drugset / Trial / NCT02709876
Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa
NaSingle-groupOpen-labelTreatment
Summary
A single arm, single center trial to evaluate the safety and efficacy of autologous purified populations of bone-marrow derived stem cells in patients with Retinitis Pigmentosa (BM-SCs) through a 48 month follow up period.
Timeline
- Start
- 2014-04
- Primary completion
- 2020-09
- Completion
- 2021-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD34+, CD133+, CD271+ stem cells | Unknown | — | Intravitreal |